title: Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients.
abstract: The aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid ((153)Sm-EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff's finger. Urine samples were collected from 11 patients after intravenous injection of (153)Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 µSv h(-1) for within 1 h following (153)Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved (153)Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week.
authors: Department of Nuclear Medicine, Celal Bayar University, Medical School, Manisa, Turkey yasemin.gultekin@hotmail.com.
authors: Yasemin
authors: Y
authors: Parlak
authors: Department of Nuclear Medicine, Celal Bayar University, Medical School, Manisa, Turkey.
authors: Gul
authors: G
authors: Gumuser
authors: Department of Nuclear Medicine, Celal Bayar University, Medical School, Manisa, Turkey.
authors: Elvan
authors: E
authors: Sayit
mesh_terms: D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000652:urine; D001859:Bone Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D016273:Occupational Exposure / Q000032:analysis*; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine; D012867:Skin / Q000528:radiation effects*; D014018:Tissue Distribution
chemical_list: D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D019275:Radiopharmaceuticals; C061972:samarium Sm-153 lexidronam